Omnichannel - digital lead a.i. In short, this is what we are trying to do at this campus today—saving or improving patients’ lives worldwide with our innovative products. She refers to her art as a “picture essay about this exasperating, mysterious, unpredictable, motivating, fascinating, relentless nuisance.” For the campus particularly, we need to ensure that investments continue to follow here. Available at: https://www.jnj.com/janssen-announces-u-s-fda-breakthrough-therapy-designation-granted-for-jnj-6372-for-the-treatment-of-non-small-cell-lung-cancer. Leading the Strategic Compliance Team within Janssen Benelux. May 2013 – Feb 2016 2 years 10 months. In the early eighties this was a deadly disease but now, at least in the developed world, it is a chronic disease.
IT Lead CRM Janssen Cilag Benelux. For more info, Privacy Janssen has been one of the few companies that really managed to break into the global arena to become known as one of the most innovative companies in the world. Nonetheless, for us it is important to continue to invest in the country as it represents the very roots of Janssen. If we obtain approval for innovative new compounds we already have a number of universities and key opinion leaders who have previously worked with the compound during the clinical research phase. This indicates that not only do we consider a target pipeline and portfolio in our acquisitions, but also its culture and expertise. We use cookies to ensure that we give you the best experience on our site. 2017 May; 9(5): 52.

Accessed September 2020. In Conversation. Risks and uncertainties include, but are not limited to: challenges and uncertainties inherent in product research and development, including the uncertainty of clinical success and of obtaining regulatory approvals; uncertainty of commercial success; manufacturing difficulties and delays; competition, including technological advances, new products and patents attained by competitors; challenges to patents; product efficacy or safety concerns resulting in product recalls or regulatory action; changes in behaviour and spending patterns of purchasers of health care products and services; changes to applicable laws and regulations, including global health care reforms; and trends toward health care cost containment.
We focus on areas of medicine where we can make the biggest difference: Cardiovascular & Metabolism, Immunology, Infectious Diseases & Vaccines, Neuroscience, Oncology and Pulmonary Hypertension. What would you say are your strongest therapeutic areas in Belgium? Phone: +1 732-524-2955, This press release contains "forward-looking statements" as defined in the Private Securities Litigation Reform Act of 1995 regarding product development and the potential benefits and treatment impact of amivantamab and lazertinib. We do not capture any email address.

From our point of view we have to continue looking for innovating solutions not only in medication but also in services and support to patients while also becoming more efficient and effective in everything we do, like everybody else at the moment. However, we should not necessarily view this only as negative l since it encourages us to do a better job in documenting and demonstrating true clinical and societal value of our medications to our stakeholders. & Cookies. SW: One of the risks we face today is the probability of success for new compounds.

NOTE: We only request your email address so that the person you are recommending the page to knows that you wanted them to see it, and that it is not junk mail. Last accessed September 2020. “We are encouraged by these results that suggest amivantamab in combination with lazertinib may be a promising option in this specific disease cohort where a high unmet need remains for more targeted treatment options.”, For the 91 treated patients, the majority of treatment-related adverse events (AEs) experienced were Grade 1-2.3 A low incidence of Grade ≥3 treatment-related AEs occurred, which included rash (four percent), hypoalbuminemia (two percent), increased gamma glutamyltransferase (one percent), hyponatraemia (one percent) paronychia (one percent) and interstitial lung disease (one percent).3 Related AEs leading to treatment discontinuation occurred in six percent of patients.3 Infusion-related reaction occurred predominantly at first infusion and did not impact subsequent dosing.3, The results from the CHRYSALIS study have led to new studies to further evaluate the potential of amivantamab and lazertinib combination therapy. At Janssen, we are committed to developing innovative targeted therapies that address the unmet needs for specific types of lung cancer, such as those with EGFR-mutated non-small cell lung cancer,” said Joaquín Casariego, M.D., Janssen Therapeutic Area Lead Oncology for Europe, Middle East & Africa, Janssen-Cilag, S.A. “The interim data from the evaluation of amivantamab and lazertinib in combination demonstrate encouraging potential for providing new treatment options for the advanced NSCLC patient population.”, Amivantamab, formerly JNJ-61186372, is an investigational EGFR-MET bispecific antibody with immune cell-directing activity that targets activating and resistance EGFR mutations and MET mutations and amplifications.3,5 In March 2020, amivantamab received Breakthrough Therapy Designation from the U.S. Food and Drug Administration (FDA) for the treatment of patients with metastatic NSCLC with EGFR exon 20 insertion mutations whose disease has progressed on or after platinum-based chemotherapy.8 These results were also presented at the American Society of Clinical Oncology (ASCO) 2020 Scientific Program.9 The production and development of the antibody followed Janssen Biotech, Inc.’s licensing agreement with Genmab for use of its DuoBody® technology platform.10, Lazertinib is an oral, third-generation, brain-penetrant, EGFR TKI that targets both the T790M mutation and activating EGFR mutations while sparing wild type-EGFR.11 Interim safety and efficacy results from the lazertinib Phase 1-2 study were published in The Lancet Oncology in 2019.2 In 2018, Janssen Biotech, Inc. entered into a license and collaboration agreement with Yuhan Corporation for the development of lazertinib.12, In Europe, it is estimated that over 470,000 patients were diagnosed with lung cancer in 2018, with around 85 percent diagnosed with NSCLC.13,14 Lung cancer is Europe’s biggest cancer killer, with more deaths than breast cancer and prostate cancer combined.13 The five-year survival rate for patients with metastatic NSCLC is currently 24 percent.15, The main subtypes of NSCLC are adenocarcinoma, squamous cell carcinoma and large cell carcinoma.16 Among the most common driver mutations in NSCLC are alterations in EGFR, which is a receptor tyrosine kinase that helps cells grow and divide.16 EGFR mutations are present in 10 to 15 percent of Caucasian patients with NSCLC and occur in 40 to 50 percent of Asian patients who have NSCLC adenocarcinoma.17,18,19, About the Janssen Pharmaceutical Companies of Johnson & Johnson. We are your one gateway to innovation and partnerships in the Benelux region. Janssen Research & Development, LLC, Janssen-Cilag S.A. and Janssen Biotech, Inc. are part of the Janssen Pharmaceutical Companies of Johnson & Johnson. Moreover, I want people here to understand that their contributions at Janssen have an impact on patients’ lives because everyone who works here touches people’s lives. Tom Heyman – CEO, Janssen Pharmaceutica & Sonja Willems – Managing Director, Janssen Benelux . We firmly believe that if we continue to bring value to society and answer the specific clinical needs of patients, our success will be carried into the future. This undoubtedly demonstrates yet another example of Janssen’s ability to innovate. This represents the first tuberculosis product in 40 years that will be introduced to the market. Your one gateway to innovation and partnerships in the Benelux region. What core values and spirit of Dr. Paul Janssen were you asked by the Janssen family to perpetuate throughout the years? I would attribute my success to a little bit of luck and to the guidance of great mentors around me. The new Belgian government has moved to streamline its response to the COVID-19 crisis with the appointment of Pedro Facon, director general for health at Belgium's Federal Public Service Health…, In late 2019 Novartis hit the headlines in Belgium after it refused to grant access to its one-off gene therapy…, Belgium’s healthcare system was ranked fourth in Europe in 2019, outperforming its peers across a number of…, Squirreled away in the lowlands of North West Europe and somewhat dwarfed by the mighty neighbouring pharmaceutical…, Carl Laurent, managing director and CEO of Siemens Healthineers BeLux, sits down with PharmaBoardroom to explain Siemens Healthineers’ footprint and impact in Belgium and Luxembourg, the importance of appreciating diagnostics as a means of cost reduction in healthcare, and the need to ensure access to the latest medtech innovations. Main tasks: - P&L responsibility Janssen Cilag Belgium - Actuals versus budget analyses - Sales and opex forecasting - finance support to business partners - Reporting - Ad hoc projects - Tax recuperation responsiblity. 17 Pao W, Girard N. New driver mutations in non-small-cell lung cancer. We have a dedicated and professional workforce here and the Belgium government has created a good environment especially from a fiscal point of view to conduct R&D.

Furthermore, we have to open ourselves to the external environment and realize that there is more innovation going on outside our walls.

The industry is not able to solve this alone so has to sit with partners in order to find the right solutions.

Genmab Enters Broad Collaboration with Janssen Biotech, Inc. for DuoBody Platform. Français | Thank you for your interest in spreading the word about Janssen Belgium. Janssen Cilag Benelux. We’re the Pharmaceutical Companies of Johnson & Johnson, working tirelessly to make that future a reality for patients everywhere by fighting sickness with science, improving access with ingenuity and healing hopelessness with heart. 6 Hong, W. et al. Business Unit Finance Manager Benelux Antwerp Area, ... Janssen Inc. Activity. Can you elaborate to our readers what you meant by this and provide us with an insight into the future direction of Janssen’s research model? Email: NReymond@its.jnj.com, Sarah Jones E.g. More specifically, highly developed markets have governments that play a major role in how healthcare is provided and paid for. Noah Reymond We have to be able to demonstrate through studies, as well as through solid relationships with authorities, that we can help authorities manage their budgets together with providing better solutions for patients. In other words, because we did not want to make compromises we had to endure some tough times but I believe that today we are reaping the benefits of those choices as we are now capable of delivering true value and innovation to our patients and society. Amivantamab (JNJ-61186372), an EGFR-MET bispecific antibody, in combination with lazertinib, a 3rd-generation tyrosine kinase inhibitor (TKI), in advanced EGFR NSCLC. 20 (12): 1681-1690.